A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique
Withdrawn · Phase 2 · NCT05606757
Conditions: Ventral Hernia, Abdominal Hernia
At a glance
- Research payments reported, 2025
- $9,200
- U.S. investigators named
- 1
- Sites paid
- 1
About the trial
- Sponsor
- AbbVie
- Tested
- BOTOX Dose A (drug), Placebo for BOTOX (drug), BOTOX Dose B (drug), BOTOX Dose C (drug)
- Dates
- Started 2024-05-07; completion 2025-09-26
- Results posted
- Not yet
Ventral hernias form when there is a loss of integrity of the abdominal wall muscles. Abdominal hernias can expand and can cause severe pain as the abdominal wall weakens. The purpose of this study is to evaluate the safety and efficacy of a range of onabotulinumtoxinA (BOTOX) doses to achieve primary fascial closure (PFC) without use of component separation technique (CST) in ventral hernia surgical repair. BOTOX is an investigational drug being developed for the treatment of ventral hernias. In this dose escalation study, participants will be placed in 1 of 3 cohorts. Cohort 1 will be randomized to receive placebo or 1 of 2 BOTOX doses, after which time Cohort 2 will be randomized to re…
From ClinicalTrials.gov, last updated 2024-05-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $9,200 in research payments for this study in 2025 (1 payments).
Products named: Botox
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.